HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--May 30, 2008 - Nymox
Pharmaceutical Corporation (NASDAQ: NYMX) today announced that new
clinical trial data concerning the safety and efficacy of the
Company's NX-1207 for benign prostatic hyperplasia (BPH) will be
presented at the Northeastern Section of the American Urological
Association Meeting on September 18. The paper is authored by
leading clinical research investigators participating in the U.S.
clinical trials of NX-1207.

NX-1207 is Nymox's patented drug candidate for the treatment of
BPH, a common affliction of men related to enlarged prostate.
Blinded clinical trials to date have shown that men treated with
NX-1207 reported statistically significant improvement in BPH
symptoms 3 months after a single NX-1207 treatment with no reported
serious drug-related side effects, including no significant sexual
side effects.

Results of 6 follow-up studies of available subjects from
NX-1207 clinical trials have provided evidence of durable benefits
from NX-1207 treatment for up to 4 1/2 years from the date of
treatment. The Company recently announced statistically significant
improvement compared to placebo in a 22 to 33 month follow-up study
of 93 patients treated with NX-1207 at 17 U.S. clinical trial
sites. Results in that study showed that patients at follow-up
without any other treatment for BPH had a mean of 11.3 points BPH
Symptom Score reduction, which represents a 47% improvement in
symptoms from before treatment.

BPH treatment represents a growing market with more than 100
million men worldwide being estimated to suffer from BPH symptoms.
The disorder is a common affliction of older men, affecting
approximately half of men over age 50 and close to 90% of men by
age 80, and is associated with growth in prostate size as men age.
BPH causes difficulties with urination associated with aging, such
as urination at night, urge to void frequently, hesitancy, weak
stream, and other problems, and can cause acute urinary retention
requiring immediate medical attention.

More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. The
conduct of clinical trials and the development of drug products
involve substantial risks and uncertainties and actual results may
differ materially from expectations. Promising early results do not
ensure that later stage or larger scale clinical trials will be
successful or will proceed as expected. Such factors are detailed
from time to time in Nymox's filings with the United States
Securities and Exchange Commission and other regulatory
authorities.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.